Talon Biomarkers’ Role in Precision Drug Development

Interview with Pratip Chattopadhyay, Founder and CEO of Talon Biomarkers By Caitlin Dolegowski, Marketing Manager, LSN

Pratip Chattopadhyay

Caitlin Dolegowski

In this interview, Pratip Chattopadhyay, Founder and CEO of Talon Biomarkers, shares the journey behind the company’s founding and its mission to improve cancer recurrence predictions through advanced immune cell characterization. As a sponsor at the upcoming RESI Boston, Pratip delves into Talon’s cutting-edge technologies, strategic collaborations, and what excites them about connecting with early-stage companies in the biotech space.

Caitlin Dolegowski (CD): Can you tell us about Talon Biomarkers’ founding story and mission?

Pratip Chattopadhyay (PC): Talon Biomarkers was born from my personal frustration with understanding cancer recurrence risks and a broader need in drug development for precise cell-type markers that predict therapeutic outcomes. My career has been dedicated to developing the technologies that accurately characterize immune cells, and Talon is where we connect these technical capabilities to drug discovery and informed patient treatment decision-making.

CD: What sets Talon Biomarkers apart from other biomarker discovery companies?

PC: At Talon, we believe that every patient sample and clinical trial holds valuable insights—there’s always something to learn, even when outcomes aren’t as expected. We leverage cutting-edge, high-parameter immune monitoring technologies to identify predictors of therapeutic efficacy and disease progression. While we operate as a CRO, what truly sets us apart is our deep scientific commitment. We collaborate closely with our clients’ translational teams, not just delivering data but helping to analyze and interpret it, ensuring every experiment reveals actionable insights.

CD: How do you collaborate with clients on experimental design and data interpretation?

PC: We’ve developed unique, automated approaches to accelerate experimental design and execution, ensuring that our work is robust and impactful. Our process starts with understanding the client’s needs through one-on-one consultations and tailoring our strategies to fit their budget and goals, delivering actionable insights.

CD: Can you discuss your strategic partnership with LASE Innovation and how it enhances your services?

PC: Our partnership with LASE Innovation showcases Talon’s tech development expertise. We help companies validate, demonstrate, and introduce new technologies to the scientific community. LASE, for instance, has an exciting technology that transforms static flow cytometry results into dynamic time-lapse insights on immune responses, pushing the boundaries of traditional immune monitoring.

CD: What types of early-stage companies are you most excited to connect with at RESI Boston?

PC: We’re eager to connect with companies developing drugs that affect the immune system or involve immune responses in disease settings. The immune system often serves as a sentinel for many diseases and drug reactions, and we’re excited to demonstrate how our tools can accelerate discoveries.

CD: What emerging trends do you see in immune monitoring and biomarker research?

PC: One major trend is the simultaneous measurement of multiple immune cell parameters, maximizing insights from valuable patient samples. Another is the advancement in complex data analysis. As thought leaders, we guide our clients toward the best biomarker discovery approaches that yield actionable insights.

CD: How can interested companies best engage with Talon Biomarkers during and after RESI Boston?

PC: We’d love to meet you at Table 20, and don’t miss our Wednesday afternoon workshop at 2PM on the third floor of the Westin, St George Room D! If you can’t attend RESI, you can schedule a one-on-one meeting through our website. We look forward to connecting!